Sinomenine Inhibits the Growth of Ovarian Cancer Cells Through the Suppression of Mitosis by Down-Regulating the Expression and the Activity of CDK1

被引:13
|
作者
Qu, Xiaoyan [1 ]
Yu, Bing [2 ]
Zhu, Mengmei [2 ]
Li, Xiaomei [2 ,3 ]
Ma, Lishan [1 ]
Liu, Chuyin [1 ]
Zhang, Yixing [1 ]
Cheng, Zhongping [4 ]
机构
[1] Tongji Univ, Yangpu Hosp, Dept Gynecol & Obstet, Sch Med, Shanghai 200090, Peoples R China
[2] Second Mil Med Univ, Navy Med Univ, Dept Cell Biol, Shanghai 200433, Peoples R China
[3] Zunyi Med Univ, Affiliated Hosp, Canc Res Lab, Zunyi 563003, Guizhou, Peoples R China
[4] Tongji Univ, Shanghai Peoples Hosp 10, Dept Gynecol & Obstet, Sch Med, 301 Yanchang Middle Rd, Shanghai 200072, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2021年 / 14卷
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
ovarian cancer; sinomenine; high throughput RNA-seq; CDK1; cell proliferation; PHOSPHORYLATION; POLO; PROLIFERATION; PATHWAY; BINDING; KINASE; BUB1;
D O I
10.2147/OTT.S284261
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Ovarian cancer is one of the most common gynecological cancers worldwide. While, therapies against ovarian cancer have not been completely effective, sinomenine has been proved to have anti-tumor activity in various cancer cells. However, study of its anti-ovarian cancer effect is still rare, and the underlying mechanism has not been elucidated. Therefore, we aim to explore the mechanism of sinomenine anti-ovarian cancer. Materials and Methods: The effect of anti-ovarian cancer HeyA8 cells was analyzed by CCK8 and colony formation assay. The mechanism of sinomenine anti-ovarian cancer was explored via high throughput RNA-seq, and then the target mRNA and protein expression were verified by real-time PCR and Western blot, respectively. Results: We found that the proliferation and clone formation ability of ovarian cancer HeyA8 cells were markedly reduced by 1.56 mM sinomenine. The transcriptome analysis showed that 2679 genes were differentially expressed after sinomenine treatment in HeyA8 cells, including 1323 down-regulated genes and 1356 up-regulated genes. Gene ontology and KEGG pathway enrichment indicated that differential expression genes (DEGs) between the groups of sinomenine and DMSO-treated HeyA8 cells were mainly involved in the process of the cell cycle, such as kinetochore organization, chromosome segregation, and DNA replication Strikingly, the top 18 ranked degree genes in the protein-protein interaction (PPI) network were mainly involved in the process of mitosis, such as sister chromatid segregation, condensed chromosome, and microtubule cytoskeleton organization. Moreover, real-time PCR results showed consistent expression trends of DEGs with transcriptome analysis. The results of Western blot showed the expression level of CDK1, which was the highest degree gene in PPI and the main regulator controlling the process of mitosis, and the levels of phosphorylated P-CDK (Thr161) and P-Histone H3 (Ser10) were decreased after being treated with sinomenine. Conclusion: Our results demonstrated that sinomenine inhibited the proliferation of HeyA8 cells through suppressing mitosis by down-regulating the expression and the activity of CDK1. The study may provide a preliminary research basis for the application of sinomenine in anti-ovarian cancer.
引用
收藏
页码:823 / 834
页数:12
相关论文
共 50 条
  • [41] Hath1 Inhibits Proliferation of Colon Cancer Cells Probably Through Up-regulating Expression of Muc2 and p27 and Down-regulating Expression of Cyclin D1
    Zhu, Dai-Hua
    Niu, Bai-Lin
    Du, Hui-Min
    Ren, Ke
    Sun, Jian-Ming
    Gong, Jian-Ping
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6349 - 6355
  • [42] Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer
    Yang, Wookyeom
    Cho, Hanbyoul
    Shin, Ha-Yeon
    Chung, Joon-Yong
    Kang, Eun Suk
    Lee, Eun-Ju
    Kim, Jae-Hoon
    ONCOTARGET, 2016, 7 (31) : 49481 - 49497
  • [43] The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer
    Xi, Qinghua
    Huang, Menghui
    Wang, Yingying
    Zhong, Jianxin
    Liu, Rong
    Xu, Guiqin
    Jiang, Lifei
    Wang, Juan
    Fang, Zheng
    Yang, Shuyun
    TUMOR BIOLOGY, 2015, 36 (07) : 4939 - 4948
  • [44] Blocking BRE expression in Leydig cells inhibits steroidogenesis by down-regulating 3β-hydroxysteroid dehydrogenase
    Miao, J
    Chan, KW
    Chen, GG
    Chun, SY
    Xia, NS
    Chan, JYH
    Panesar, NS
    JOURNAL OF ENDOCRINOLOGY, 2005, 185 (03) : 507 - 517
  • [45] Methyl-indole inhibits pancreatic cancer cell viability by down-regulating ZFX expression
    Qin, Xueliang
    Cui, Xiaopeng
    3 BIOTECH, 2020, 10 (04)
  • [46] Pregnane X receptor inhibits the transdifferentiation of hepatic stellate cells by down-regulating periostin expression
    Sato, Takumi
    Shizu, Ryota
    Baba, Ryonosuke
    Ooka, Akira
    Hosaka, Takuomi
    Kanno, Yuichiro
    Yoshinari, Kouichi
    BIOCHEMICAL JOURNAL, 2024, 481 (18) : 1173 - 1186
  • [47] Methyl-indole inhibits pancreatic cancer cell viability by down-regulating ZFX expression
    Xueliang Qin
    Xiaopeng Cui
    3 Biotech, 2020, 10
  • [48] Histone deacetylase SIRT6 inhibits glioma cell growth through down-regulating NOTCH3 expression
    Chen, Xin
    Li, Deheng
    Gao, Yang
    Cao, Yiqun
    Hao, Bin
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (04) : 417 - 424
  • [49] Curcumin Inhibits the Migration and Invasion of Mouse Hepatoma Hca-F Cells Through Down-regulating Caveolin-1 Expression and Epidermal Growth Factor Receptor Signaling
    Wang, Shujing
    Yu, Shengjin
    Shi, Wei
    Ge, Liang
    Yu, Xiao
    Fan, Jianhui
    Zhang, Jianing
    IUBMB LIFE, 2011, 63 (09) : 775 - 782
  • [50] Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression
    Huang, Wen-Shih
    Lin, Chien-Tsong
    Chen, Cheng-Nan
    Chang, Shun-Fu
    Chang, Hsin-I
    Lee, Ko-Chao
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (08) : 6943 - 6952